4.7 Article

Hormone replacement therapy and asthma onset in menopausal women: National cohort study

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 147, 期 5, 页码 1662-1670

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2020.11.024

关键词

Asthma; estrogens; epidemiology; estradiol; progestogen

资金

  1. Asthma UK [AUK-IG-2016-346]
  2. Health Data Research UK
  3. Knut and Alice Wallenberg Foundation
  4. Wallenberg Centre for Molecular and Translational Medicine, OPC, OPRI, University of Gothenburg, Sweden
  5. VBG Group Herman Krefting Foundation on Asthma and Allergy

向作者/读者索取更多资源

In a 17-year study, researchers found an association between hormonal replacement therapy (HRT) and a reduced risk of late onset asthma in menopausal women, with a dose-response relationship showing that longer duration of HRT use was linked to a greater reduction in asthma onset risk.
Background: There is uncertainty about the role of hormonal replacement therapy (HRT) in the development of asthma. Objective: We investigated whether use of HRT and duration of use was associated with risk of development of asthma in perimenopausal and postmenopausal women. Methods: We constructed a 17-year (from January 1, 2000, to December 31, 2016) open cohort of 353,173 women (aged 46-70 years) from the Optimum Patient Care Database, a longitudinal primary care database from across the United Kingdom. HRT use, subtypes, and duration of use; confounding variables; and asthma onset were defined by using the Read Clinical Classification System. We fitted multilevel Cox regression models to estimate hazard ratios (HRs) with 95% CIs. Results: During the 17-year follow-up (1,340,423 person years), 7,614 new asthma cases occurred, giving an incidence rate of 5.7 (95% CI = 5.5-5.8) per 1,000 person years. Compared with nonuse of HRT, previous use of any (HR = 0.83; 95% CI = 0.76-0.88), estrogen-only (HR = 0.89; 95% CI = 0.84-0.95), or combined estrogen and progestogen (HR = 0.82; 95% CI = 0.76-0.88) HRT was associated with a reduced risk of asthma onset. This was also the case with current use of any (HR = 0.79; 95% CI = 0.74-0.85), estrogen-only (HR = 0.80; 95% CI = 0.73-0.87), and combined estrogen and progestogen (HR = 0.78; 95% CI = 0.70-0.87) HRT. Longer duration of HRT use (1-2 years [HR = 0.93; 95% CI = 0.87-0.99]; 3-4 years [HR = 0.77; 95% CI = 0.70-0.84]; and >= 5 years [HR = 0.71; 95% CI = 0.64-0.78]) was associated with a dose-response reduced risk of asthma onset. Conclusion: We found that HRT was associated with a reduced risk of development of late onset asthma in menopausal women. Further cohort studies are needed to confirm these findings.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据